Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial

Journal of General Internal Medicine (2021)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

US$ 39.95

Tax calculation will be finalised during checkout.

Fig. 1

References

  1. 1.

    International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation, 2017

    Google Scholar 

  2. 2.

    Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-1982

    Article  Google Scholar 

  3. 3.

    Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657

    CAS  Article  Google Scholar 

  4. 4.

    Perkovic V, Jardine M.J., Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295-2306

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Internal Medicine Department, Beaumont Hospital, Royal Oak, MI, USA

    Alexandra Halalau MD, MSc

  2. Oakland University William Beaumont School of Medicine, Rochester, MI, USA

    Alexandra Halalau MD, MSc

  3. Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

    William Fuller MD

  4. Department of Medicine, University of Washington, Seattle, WA, USA

    Stephanie Wheeler MD, MPH

Authors
  1. Alexandra Halalau MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Fuller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephanie Wheeler MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra Halalau MD, MSc.

Ethics declarations

The authors have no conflict of interest to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Halalau, A., Fuller, W. & Wheeler, S. Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-020-06216-z

Download citation